| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 13955681
[patent_doc_number] => 20190054184
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-21
[patent_title] => Targeting Macrophages to Modulate Electrical Conduction in the Heart
[patent_app_type] => utility
[patent_app_number] => 16/075931
[patent_app_country] => US
[patent_app_date] => 2017-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075931
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/075931 | Targeting Macrophages to Modulate Electrical Conduction in the Heart | Feb 12, 2017 | Abandoned |
Array
(
[id] => 11836321
[patent_doc_number] => 20170218040
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-08-03
[patent_title] => 'PROTEOLICALLY RESISTANT CYCLOTIDES WITH ANGIOTENSIN 1-7 LIKE ACTIVITY'
[patent_app_type] => utility
[patent_app_number] => 15/422376
[patent_app_country] => US
[patent_app_date] => 2017-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 19892
[patent_no_of_claims] => 44
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422376
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/422376 | PROTEOLICALLY RESISTANT CYCLOTIDES WITH ANGIOTENSIN 1-7 LIKE ACTIVITY | Jan 31, 2017 | Abandoned |
Array
(
[id] => 16738781
[patent_doc_number] => 10964443
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-30
[patent_title] => Conductive yarn
[patent_app_type] => utility
[patent_app_number] => 16/073790
[patent_app_country] => US
[patent_app_date] => 2017-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 27
[patent_no_of_words] => 22531
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16073790
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/073790 | Conductive yarn | Jan 28, 2017 | Issued |
Array
(
[id] => 16704393
[patent_doc_number] => 10954313
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-23
[patent_title] => Composition comprising SP1 and carbon based nanoparticles and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/073789
[patent_app_country] => US
[patent_app_date] => 2017-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 43
[patent_no_of_words] => 38494
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16073789
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/073789 | Composition comprising SP1 and carbon based nanoparticles and uses thereof | Jan 28, 2017 | Issued |
Array
(
[id] => 11888004
[patent_doc_number] => 09758556
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2017-09-12
[patent_title] => 'Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5'
[patent_app_type] => utility
[patent_app_number] => 15/418311
[patent_app_country] => US
[patent_app_date] => 2017-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 56
[patent_no_of_words] => 18156
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418311
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/418311 | Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5 | Jan 26, 2017 | Issued |
Array
(
[id] => 11888003
[patent_doc_number] => 09758555
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2017-09-12
[patent_title] => 'Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5'
[patent_app_type] => utility
[patent_app_number] => 15/418247
[patent_app_country] => US
[patent_app_date] => 2017-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 56
[patent_no_of_words] => 18158
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418247
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/418247 | Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5 | Jan 26, 2017 | Issued |
Array
(
[id] => 15510281
[patent_doc_number] => 10561707
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-02-18
[patent_title] => Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
[patent_app_type] => utility
[patent_app_number] => 15/413991
[patent_app_country] => US
[patent_app_date] => 2017-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 96
[patent_no_of_words] => 29330
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15413991
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/413991 | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases | Jan 23, 2017 | Issued |
Array
(
[id] => 12030812
[patent_doc_number] => 20170320911
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-09
[patent_title] => 'HIGH AFFINITY METAL-OXIDE BINDING PEPTIDES WITH REVERSIBLE BINDING'
[patent_app_type] => utility
[patent_app_number] => 15/413291
[patent_app_country] => US
[patent_app_date] => 2017-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 15331
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15413291
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/413291 | HIGH AFFINITY METAL-OXIDE BINDING PEPTIDES WITH REVERSIBLE BINDING | Jan 22, 2017 | Abandoned |
Array
(
[id] => 13840565
[patent_doc_number] => 20190023767
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-24
[patent_title] => NOVEL POLYPEPTIDES AND MEDICAL USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/066912
[patent_app_country] => US
[patent_app_date] => 2017-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20648
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16066912
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/066912 | Polypeptides and medical uses thereof | Jan 19, 2017 | Issued |
Array
(
[id] => 13297573
[patent_doc_number] => 20180200323
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-19
[patent_title] => USE OF TETRAPEPTIDE -3 GEKG OR PENTAPEPTIDE -3 GEKGF FOR TREATING DEGENERATIVE JOINT DISEASE
[patent_app_type] => utility
[patent_app_number] => 15/406912
[patent_app_country] => US
[patent_app_date] => 2017-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2073
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15406912
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/406912 | USE OF TETRAPEPTIDE -3 GEKG OR PENTAPEPTIDE -3 GEKGF FOR TREATING DEGENERATIVE JOINT DISEASE | Jan 15, 2017 | Abandoned |
Array
(
[id] => 13790793
[patent_doc_number] => 20190008935
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-10
[patent_title] => METHODS AND USES FOR ALPHA-1 ANTITRYPSIN OR RECOMBINANT FORMS THEREOF, ON STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE INVOLVING GASTROINTESTINAL COMPLICATIONS
[patent_app_type] => utility
[patent_app_number] => 16/067076
[patent_app_country] => US
[patent_app_date] => 2016-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12636
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16067076
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/067076 | METHODS AND USES FOR ALPHA-1 ANTITRYPSIN OR RECOMBINANT FORMS THEREOF, ON STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE INVOLVING GASTROINTESTINAL COMPLICATIONS | Dec 29, 2016 | Abandoned |
Array
(
[id] => 16430683
[patent_doc_number] => 10830762
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-10
[patent_title] => Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
[patent_app_type] => utility
[patent_app_number] => 16/066288
[patent_app_country] => US
[patent_app_date] => 2016-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 62
[patent_figures_cnt] => 49
[patent_no_of_words] => 458790
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 257
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16066288
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/066288 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | Dec 26, 2016 | Issued |
Array
(
[id] => 13777983
[patent_doc_number] => 20190002530
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-03
[patent_title] => GELATIN PARTICLES, METHOD FOR PRODUCING GELATIN PARTICLES, GELATIN PARTICLE-CONTAINING CELL, AND METHOD FOR PRODUCING GELATIN PARTICLE-CONTAINING CELL
[patent_app_type] => utility
[patent_app_number] => 16/064828
[patent_app_country] => US
[patent_app_date] => 2016-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6638
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16064828
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/064828 | GELATIN PARTICLES, METHOD FOR PRODUCING GELATIN PARTICLES, GELATIN PARTICLE-CONTAINING CELL, AND METHOD FOR PRODUCING GELATIN PARTICLE-CONTAINING CELL | Dec 18, 2016 | Abandoned |
Array
(
[id] => 11820583
[patent_doc_number] => 20170209521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-07-27
[patent_title] => 'SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS'
[patent_app_type] => utility
[patent_app_number] => 15/372229
[patent_app_country] => US
[patent_app_date] => 2016-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 15387
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15372229
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/372229 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | Dec 6, 2016 | Abandoned |
Array
(
[id] => 13899021
[patent_doc_number] => 20190038715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-07
[patent_title] => PEPTIDES DERIVED FROM ACTIN-LIKE PROTEIN 8 (ACTL8)
[patent_app_type] => utility
[patent_app_number] => 15/777144
[patent_app_country] => US
[patent_app_date] => 2016-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9676
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777144
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/777144 | Peptides derived from actin-like protein 8 (ACTL8) | Nov 22, 2016 | Issued |
Array
(
[id] => 16695536
[patent_doc_number] => 10946105
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-16
[patent_title] => Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules
[patent_app_type] => utility
[patent_app_number] => 15/778206
[patent_app_country] => US
[patent_app_date] => 2016-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 18
[patent_no_of_words] => 9783
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15778206
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/778206 | Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules | Nov 22, 2016 | Issued |
Array
(
[id] => 16695536
[patent_doc_number] => 10946105
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-16
[patent_title] => Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules
[patent_app_type] => utility
[patent_app_number] => 15/778206
[patent_app_country] => US
[patent_app_date] => 2016-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 18
[patent_no_of_words] => 9783
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15778206
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/778206 | Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules | Nov 22, 2016 | Issued |
Array
(
[id] => 16695536
[patent_doc_number] => 10946105
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-16
[patent_title] => Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules
[patent_app_type] => utility
[patent_app_number] => 15/778206
[patent_app_country] => US
[patent_app_date] => 2016-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 18
[patent_no_of_words] => 9783
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15778206
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/778206 | Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules | Nov 22, 2016 | Issued |
Array
(
[id] => 16695536
[patent_doc_number] => 10946105
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-16
[patent_title] => Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules
[patent_app_type] => utility
[patent_app_number] => 15/778206
[patent_app_country] => US
[patent_app_date] => 2016-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 18
[patent_no_of_words] => 9783
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15778206
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/778206 | Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules | Nov 22, 2016 | Issued |
Array
(
[id] => 16649992
[patent_doc_number] => 10927155
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-23
[patent_title] => Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta
[patent_app_type] => utility
[patent_app_number] => 15/776932
[patent_app_country] => US
[patent_app_date] => 2016-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 29
[patent_no_of_words] => 26380
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 133
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776932
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/776932 | Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta | Nov 17, 2016 | Issued |